Welcome back to Squat Fox. Five things to know ahead of the opening bell. Fizer winning a bidding war for the obesity drug developer Metsera.Now Metser is accepting a sween offer from Fizer late Friday citing US antitrust risks from another bid by Novo Nordisk. Meanwhile, shares of Dagio, they're higher. The company has appointed the former CEO of UK grosser giant Tesco as its new CEO.Dave Lewis is going to be taking over at the start of 2026. and UPS and FedEx grounding their combined fleet now of more tha ...

Novo Nordisk is out with results this morning now lowering its fullear profit uh and revenue uh forecast. Meanwhile, uh the company it's it's getting very interesting in terms uh of uh this possible uh bidding war uh that uh that we are seeing as we move that up a little bit please. That's what this means.Yeah, there you go. Keep going. Keep going. Keep going.Joining us now, Novo Nordis CEO Mike Dudstar. It's good to have you on. Uh can we talk uh about how much this is uh cherished this company met very sm ...

Third quarter results just out from WGOI maker Novo Nordisk. The Danish company lowering its fullear profit and revenue forecast. Novo CEO citing lower growth expectations for GLP-1 treatments.Separately, the Wall Street Journal now saying the White House speaking with Nova Nordis and Eli Liy about making some of their obesity drugs available on a proposed government-run website for $149 a month. The report says Medicare and Medicaid would cover the drugs for weight loss. We're going to speak with the CEO o ...